MitoStem

MPC Therapeutics is a Swiss biotechnology company specializing in mitochondrial metabolic reprogramming to rejuvenate cells and enhance therapeutic outcomes. The company's lead platform, MitoStem™, is a first-in-class small molecule metabolic enhancer designed to improve the quality and durability of CAR-T and other engineered cell therapies by increasing the frequency of stem cell memory T cells (Tscm). In addition to its commercial-stage reagents for cell therapy manufacturing, MPC Therapeutics is developing a pipeline of therapeutic candidates targeting the Mitochondrial Pyruvate Carrier (MPC) for chronic diseases such as kidney fibrosis and Alzheimer's. Founded in 2018 as a spin-off from the University of Geneva, the company leverages deep expertise in mitochondrial biology to address significant unmet medical needs in oncology, nephrology, and neurology.